Top Industry Leaders in the Vaccine Conjugates Market
Latest Vaccine Conjugates Companies Updates
Pfizer Inc. (US): Received FDA approval for its Prevnar 20® pneumococcal conjugate vaccine for adults in October 2023, expanding its market reach and potential revenue stream.
Merck & Co., Inc. (US): Partnered with PATH (US) in September 2023 to develop and introduce a new MenB vaccine conjugate for low- and middle-income countries, addressing global health disparities.
GlaxoSmithKline plc (UK): Highlighted its ongoing development of a malaria vaccine conjugate in its recent investor presentation, showcasing its commitment to innovative vaccine solutions.
Bharat Biotech International Limited (India): Announced successful Phase 3 clinical trials for its Typhoid Conjugate Vaccine in July 2023, paving the way for potential market entry and wider access to this important vaccine.
Novavax, Inc. (US): Presented promising preclinical data for its respiratory syncytial virus (RSV) F protein conjugate vaccine candidate in September 2023, adding to the pipeline of potential new conjugate vaccines.
List of Vaccine Conjugates Key companies in the market:
- Bharat Biotech (India)
- GlaxoSmithKline Plc (UK)
- Serum Institute of India
- Sanofi Pasteur (France)
- Merck and Company (US)
- CSL Limited (Australia)
- Pfizer Inc. (US)
- Novartis AG (Switzerland)
- Neuron Biotech (the US)
- Biological E (India)